As ImmusanT initiates the process to develop its treatment regimens for celiac disease and Type 1 diabetes, the company has fast-paced its hiring activity by bringing on board Ken Truitt M.D. Daiichi Sankyo’s SVP for internal medicine therapeutics as its new Chief Medical Officer. New VPs have also been put in place by the company for looking after program management and clinical operations.

In a previous stint, Truitt worked as the Japanese pharma company’s global head of translational medicine and clinical pharmacology and also served as VP of clinical development. Prior to that, he served as director of clinical research at the pulmonary-immunology division of Merck.

Kristin Neff has been hired as VP of clinical operations and project management, Joyce Pinkham as VP of program management and Jonathan Yeodon as finance director by the Cambridge, Massachusetts-based Immusan T. Neff earlier worked as VP of clinical operations and project management at InVivo Therapeutic and has been instrumental in developing a medical device for treating acute spinal cord injury. Pinkham has worked in her former stint as VP of program and alliance management at Juniper Pharmaceuticals. She has also served in senior positions in program and portfolio management at Cubist Pharmaceuticals and Genzyme.